A Refined Estimate of the Lifetime Cost of Pelvic Inflammatory Disease

Sexually Transmitted Diseases

Volumn 31, Issue 5, 2004, Pages 325-

  Rein, David B ^a   Gift, Thomas L ^b  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANALYTICAL ERROR; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; HEALTH INSURANCE; HUMAN; LETTER; MEDICAID; MEDICAL RESEARCH; MONEY; PEER REVIEW; PELVIC INFLAMMATORY DISEASE; PROBABILITY; PUBLICATION;

COST OF ILLNESS; FEMALE; HUMANS; MODELS, ECONOMETRIC; PELVIC INFLAMMATORY DISEASE; UNITED STATES;

EID: 2142660710     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200405000-00013     Document Type: Letter

References (5)

1. Yeh J, Hook E III, Goldie S. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003;30:369-378.
2. Washington A, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections 1983 through 2000. JAMA 1991;266:2565-2569.
3. Magid D, Douglas J, Schwartz J. Doxycycline compared with azithromycin for treating women with genital chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996;124:389-399.
4. Rein D, Kassler W, Irwin K, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial. Obstet Gynecol 2000;95:397-402.
5. Anonymous. Chlamydia. In: Stratton K, Durch J, Lawrence R, eds. Vaccines for the 21st Century: A Tool for Decision Making. Washington, DC: National Academy Press, 2000.